ERIS LIFESCIENCES LIMITED Q3FY22 REVENUES AT INR 3,322 MN, UP 7.0% YOY

Consolidated Financial Highlights:

Particulars
(INR million)
Q3FY22 Q3FY21 YoY (%) 9MFY22 9MFY21 YoY (%)
Revenue 3,322 3,104 7.0% 10,411 9,337 11.5%
Gross Profit 2,707 2,540 6.6% 8,444 7,558 11.7%
EBITDA 1,217 1,072 13.5% 3,881 3,361 15.5%
EBITDA Margin 36.6% 34.5% 210bps 37.3% 36.0% 128bps
PAT 1,008 902 11.8% 3,258 2,869 13.6%
PAT Margin 30.3% 29.0% 130bps 31.3% 30.7% 57bps

 

Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “Eris has demonstrated a 2-year CAGR of 14% since pre-Covid levels, which is nearly twice of the IPM growth of 7% p.a. Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory.”

Mr. Krishnakumar V, Executive Director & Chief Operating Officer of Eris Lifesciences Ltd., added, “We are on track to deliver an EPS growth of 14-15% in FY22, on the back of a 21% EPS growth delivered in FY21. We launched 4 new products in the first 9 months of FY22; we have several new launches planned in Diabetes, CNS, Wellness and Women’s Health in Quarter 4.”

News Links

Copyright © 2022 Eris Lifesciences Limited. All Rights Reserved.